Lineage Cell Therapeutics, Inc. (LCTX) stock
LCTXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/3021% above fair value
$0.80−0.12 (-13.07%)
Close on Nov 16, 2026Market cap $201.09MP/E –Yield –
Lineage Cell Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Lineage Cell Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was -$26.11M. For fiscal 2025 it was -$35.92M. The highest annual figure on record is -$20.89M in fiscal 2024.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$35.92M | – |
| FY2024 | Dec 31, 2024 | -$20.89M | – |
| FY2023 | Dec 31, 2023 | -$24.17M | – |
| FY2022 | Dec 31, 2022 | -$21.94M | – |
| FY2021 | Dec 31, 2021 | -$48.55M | – |
| FY2020 | Dec 31, 2020 | -$25.62M | – |
| FY2019 | Dec 31, 2019 | -$37.87M | – |
| FY2018 | Dec 31, 2018 | -$40.71M | – |
| FY2017 | Dec 31, 2017 | -$37.96M | – |
| FY2016 | Dec 31, 2016 | -$57.79M | – |
| FY2015 | Dec 31, 2015 | -$64.73M | – |
| FY2014 | Dec 31, 2014 | -$49.63M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$8.74M | – |
| Q1 FY2026 | Mar 31, 2026 | -$7.41M | – |
| Q4 FY2025 | Dec 31, 2025 | -$6.36M | – |
| Q3 FY2025 | Sep 30, 2025 | -$3.61M | – |
| Q2 FY2025 | Jun 30, 2025 | -$19.61M | – |
| Q1 FY2025 | Mar 31, 2025 | -$6.34M | – |
| Q4 FY2024 | Dec 31, 2024 | -$4.96M | – |
| Q3 FY2024 | Sep 30, 2024 | -$3.70M | – |
| Q2 FY2024 | Jun 30, 2024 | -$5.73M | – |
| Q1 FY2024 | Mar 31, 2024 | -$6.51M | – |
| Q4 FY2023 | Dec 31, 2023 | -$6.22M | – |
| Q3 FY2023 | Sep 30, 2023 | -$6.56M | -104.7% |
| Q2 FY2023 | Jun 30, 2023 | -$4.89M | -103.4% |
| Q1 FY2023 | Mar 31, 2023 | -$6.50M | – |
| Q4 FY2022 | Dec 31, 2022 | -$6.50M | – |
| Q3 FY2022 | Sep 30, 2022 | $139.75M | – |
| Q2 FY2022 | Jun 30, 2022 | $141.77M | – |
| Q1 FY2022 | Mar 31, 2022 | -$6.25M | – |
| Q4 FY2021 | Dec 31, 2021 | -$28.08M | – |
| Q3 FY2021 | Sep 30, 2021 | -$6.68M | – |
| Q2 FY2021 | Jun 30, 2021 | -$6.92M | – |
| Q1 FY2021 | Mar 31, 2021 | -$6.88M | – |
| Q4 FY2020 | Dec 31, 2020 | -$5.68M | – |
| Q3 FY2020 | Sep 30, 2020 | -$6.53M | – |
| Q2 FY2020 | Jun 30, 2020 | -$6.19M | – |
| Q1 FY2020 | Mar 31, 2020 | -$7.23M | – |
| Q4 FY2019 | Dec 31, 2019 | -$6.64M | – |
| Q3 FY2019 | Sep 30, 2019 | -$8.17M | – |
| Q2 FY2019 | Jun 30, 2019 | -$10.58M | – |
| Q1 FY2019 | Mar 31, 2019 | -$12.49M | – |
| Q4 FY2018 | Dec 31, 2018 | -$9.84M | – |
| Q3 FY2018 | Sep 30, 2018 | -$10.10M | – |
| Q2 FY2018 | Jun 30, 2018 | -$8.87M | – |
| Q1 FY2018 | Mar 31, 2018 | -$11.91M | – |
| Q4 FY2017 | Dec 31, 2017 | -$9.29M | – |
| Q3 FY2017 | Sep 30, 2017 | -$9.26M | – |
| Q2 FY2017 | Jun 30, 2017 | -$8.36M | – |
| Q1 FY2017 | Mar 31, 2017 | -$11.05M | – |
| Q4 FY2016 | Dec 31, 2016 | -$11.07M | – |
| Q3 FY2016 | Sep 30, 2016 | -$9.31M | – |
See a number that looks wrong?